首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl5 |
| Uniprot No | P13501 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-91aa |
| 氨基酸序列 | SPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS |
| 预测分子量 | 14.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CCL5(RANTES)重组蛋白的参考文献及其摘要概括：
1. **"Production and characterization of recombinant human CCL5/RANTES in Escherichia coli"**
- **作者**: Smith A et al.
- **摘要**: 研究描述了一种在大肠杆菌中高效表达重组人CCL5的方法，并通过Ni-NTA层析纯化获得高纯度蛋白。功能实验证实该重组蛋白具有趋化活性，可诱导单核细胞迁移，并通过受体CCR5激活下游信号通路。
2. **"Recombinant CCL5 inhibits HIV-1 entry by blocking CCR5 on CD4+ T cells"**
- **作者**: Jones B et al.
- **摘要**: 研究利用哺乳动物细胞表达的重组CCL5.验证其与HIV-1包膜蛋白竞争结合CCR5受体的能力，证明其通过抑制病毒与宿主细胞融合降低HIV感染效率，为抗病毒治疗提供潜在策略。
3. **"CCL5 promotes neutrophil recruitment in a murine model of acute lung injury"**
- **作者**: Wang C et al.
- **摘要**: 通过在小鼠急性肺损伤模型中注射重组小鼠CCL5.发现其显著增强中性粒细胞向肺组织的浸润，并加剧炎症反应，提示CCL5在炎症性疾病中的关键作用。
4. **"Structural analysis of recombinant CCL5 reveals key residues for receptor binding"**
- **作者**: Lee S et al.
- **摘要**: 通过X射线晶体学解析重组人CCL5的三维结构，鉴定出与CCR1/CCR5受体结合的关键氨基酸残基，突变实验证实这些位点对趋化活性和免疫调节功能至关重要。
(注：以上文献为示例，实际引用需根据具体研究需求检索PubMed等数据库获取真实文献。)
Ccl5 (C-C motif chemokine ligand 5), also known as RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted), is a small secreted protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, particularly T cells, monocytes, and eosinophils, to sites of inflammation or infection. Ccl5 interacts with cell surface receptors CCR1. CCR3. and CCR5. triggering intracellular signaling pathways that mediate cell migration, activation, and adhesion. Its involvement in inflammatory diseases, viral infections (notably HIV entry via CCR5 co-receptor), and cancer progression has made it a key focus of biomedical research.
Recombinant Ccl5 protein is produced using engineered expression systems, such as *E. coli*, yeast, or mammalian cells, ensuring high purity and bioactivity for experimental and therapeutic applications. This engineered form retains the native protein’s functional properties, enabling researchers to study its role in vitro and in vivo models. Recombinant Ccl5 is widely used to investigate immune cell chemotaxis, inflammatory responses, and tumor microenvironment interactions. Additionally, it serves as a tool to screen potential inhibitors or modulators targeting Ccl5-receptor interactions, with implications for treating autoimmune disorders, chronic inflammation, and HIV infection. Despite its pro-inflammatory nature, dysregulated Ccl5 expression has been linked to pathological conditions, highlighting the need for precise control in therapeutic strategies. Studies also explore its dual role in cancer—either promoting tumor immunity or supporting metastasis, depending on context—underscoring its complexity as a therapeutic target.
×
